Active substanceXantinol nicotinateXantinol nicotinate
Similar drugsTo uncover
  • Xantinol nicotinate
    solution w / m in / in 
  • Xantinol nicotinate
    solution w / m in / in 
    BINNOFARM, CJSC     Russia
  • Xantinol nicotinate
    solution w / m in / in 
  • Xantinol nicotinate
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Xantinol nicotinate
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Xantinol nicotinate
    solution w / m 
    DALHIMFARM, OJSC     Russia
  • Xantinol nicotinate
    solution w / m in / in 
  • Xantinol nicotinate
    solution w / m in / in 
    ELLARA, LTD.     Russia
  • Xanthinal nicotinate-UBF
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Dosage form: & nbsp

    solution for intramuscular injection.

    Composition:

    In 1 ml of the solution as active substance contains 150 mg of xanthinal nicotinate.

    Excipients: water for injections.

    Description:Transparent colorless liquid.
    Pharmacotherapeutic group:Vasodilator
    ATX: & nbsp

    C.04.A.D.02   Xantinol nicotinate

    Pharmacodynamics:

    Xanthinal nicotinate combines the properties of drugs of the theophylline and nicotinic acid group: it has antiaggregant effect, expands peripheral vessels, improves collateral circulation.Blocking adenosine receptors and phosphodiesterase, increases the content of cyclic adenosine monophosphate in the cell, substrate stimulates the synthesis of NAD and NAD-phosphate. It improves microcirculation, oxygenation and nutrition of tissues, with prolonged use has antiatherosclerotic effect, activates the processes of fibrinolysis, lowers the concentration of cholesterol and atherogenic lipids, increases lipoprotein lipase activity, reduces blood viscosity, reduces platelet aggregation.

    Reducing the general ceriferous vascular resistance and strengthening myocardial contractions, contributes to an increase in the minute volume of blood and increased cerebral circulation, reduces the severity of the consequences of cerebral hypoxia.

    Xanthinal nicotinate causes a "nicotine-like" syndrome, accompanied by hyperesthesia of the mucous membrane of the nasal cavity and mouth: exacerbates the sensitivity of olfactory and taste sensations. In this regard, the smell and taste of the alcoholic beverages offered during the "nicotine-like" reaction is perceived to be more harsh and unpleasant.

    Indications:

    As part of complex therapy: obliterating atherosclerosis of the vessels of the extremities, Raynaud's disease, obliterating endarteritis, diabetic angiopathy, trophic ulcers of the shins, cerebrovascular insufficiency, cerebral arteriosclerosis, cerebral circulatory disorders, coronary artery atherosclerosis, hypertriglyceridemia.

    Contraindications:

    Hypersensitivity, acute heart failure or decompensated chronic heart failure, acute bleeding, acute myocardial infarction, mitral stenosis, stomach and duodenal ulcer (in the phase of exacerbation), arterial hypotension, pregnancy, acute renal failure, glaucoma.

    Do not use in conjunction with monoamine oxidase inhibitors.

    Dosing and Administration:

    Intramuscularly.

    2-6 ml of 15% solution daily for 2-3 weeks.

    Side effects:

    Decrease in blood pressure, fever, hyperemia of the skin, weakness, dizziness, nausea, diarrhea, decreased appetite, gastralgia. With long-term administration in high doses - measurement of glucose tolerance, increased activity of "liver" transaminases and alkaline phosphatase, hyperuricemia.

    Overdose:

    Symptoms: lowering blood pressure, abdominal pain, vomiting.

    Treatment: symptomatic.

    Interaction:

    Caution should be exercised in the simultaneous administration of xanthinol nicotinate and antihypertensive medications (beta-blockers, ergot alkaloids, alpha-adrenergic blockers, sympatholytics, ganglion blockers), as well as strophanthin (strophanthin-K) (possibly sharpening their effect).

    Special instructions:

    Avoid contact with eyes or mucous membranes.

    Effect on the ability to drive transp. cf. and fur:

    Large doses can cause lower blood pressure and dizziness: apply with extreme caution to vehicle drivers.

    Form release / dosage:

    Solution for intramuscular injection 300 mg / 2 ml.

    Packaging:

    By 2 ml into ampoules of type B or type of neutral glass.

    For 10 ampoules, together with the instruction for use and the ampoule opening opener or ampoule scarifier, is placed in a cardboard box.

    5 ampoules per circuit cell packaging made of polyvinylchloride film and foil of aluminum printed lacquered or foil-free.2 contour squeeze packs with instructions for use and a knife for opening ampoules or a scarifier ampullum are placed in a pack of cardboard.

    When using ampoules with break points or rings, the ampoule opener or ampoule scaper is not inserted.

    Storage conditions:

    List B. In the dark place at a temperature of 5 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years. After the expiry date, the drug should not be used.

    Terms of leave from pharmacies:On prescription
    Registration number:P N003485 / 02
    Date of registration:25.05.2009 / 18.05.2012
    Expiration Date:Unlimited
    The owner of the registration certificate:DALHIMFARM, OJSC DALHIMFARM, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.01.2018
    Illustrated instructions
      Instructions
      Up